Molecular Pharmacology Stock Gross Profit
| MLPH Stock | USD 0.0001 0.00 0.00% |
Molecular Pharmacology fundamentals help investors to digest information that contributes to Molecular Pharmacology's financial success or failures. It also enables traders to predict the movement of Molecular Pink Sheet. The fundamental analysis module provides a way to measure Molecular Pharmacology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Molecular Pharmacology pink sheet.
Molecular |
Molecular Pharmacology Company Gross Profit Analysis
Molecular Pharmacology's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Molecular Pharmacology reported 0.0 of gross profit. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Molecular Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Pharmacology's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Molecular Pharmacology could also be used in its relative valuation, which is a method of valuing Molecular Pharmacology by comparing valuation metrics of similar companies.Molecular Pharmacology is currently under evaluation in gross profit category among its peers.
Molecular Fundamentals
| Return On Asset | -5.69 | |||
| Current Valuation | 221.59 K | |||
| Shares Outstanding | 111.55 M | |||
| Price To Earning | (0.80) X | |||
| EBITDA | (98.11 K) | |||
| Net Income | (116.93 K) | |||
| Cash And Equivalents | 1.52 K | |||
| Total Debt | 175.33 K | |||
| Current Ratio | 0.28 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (105.41 K) | |||
| Beta | 42.97 | |||
| Market Capitalization | 26.77 K | |||
| Total Asset | 8.97 K | |||
| Working Capital | (2.1 M) | |||
| Current Asset | 9 K | |||
| Current Liabilities | 2.11 M | |||
| Net Asset | 8.97 K |
About Molecular Pharmacology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Pharmacology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Pharmacology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Pharmacology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.